Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Larotrectinib. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel iodination-amination route for Larotrectinib intermediate. Enhances purity above 98.5 percent and scalability. Reliable supply chain partner for pharmaceutical manufacturing.
Novel enzyme process for chiral amine intermediate. High purity, mild conditions, scalable for pharma manufacturing.
Novel patent CN107987082A details improved Larotrectinib synthesis with lower temperatures and higher purity, offering supply chain stability and cost efficiency for pharmaceutical manufacturers.
Novel acid-catalyzed preparation method for Larotrectinib Impurity I ensures high purity and yield. Reliable pharmaceutical intermediates supplier for quality control standards.
Novel base-catalyzed racemization of larotrectinib intermediate enables recycling of S-isomer, reducing costs and waste for API manufacturing.
Patent CN112250611B reveals a novel Friedel-Crafts route for Larotrectinib intermediates. Achieve high purity and cost reduction in API manufacturing with scalable chemistry.
Patent CN116102464B details asymmetric hydrogenation for high-purity chiral amino alcohols, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.